Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist

British Journal of Pharmacology
M J RobertsonM D Dowle


1. This paper describes the effects of GR117289 (1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzo-furanyl]methyl ]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid) at angiotensin receptors and binding sites in rabbit aorta, rat liver and bovine cerebellum preparations in vitro. 2. In rabbit isolated aortic strips, GR117289 (0.3, 1 and 3 nM) caused a concentration-related, insurmountable suppression of the concentration-response curve to angiotensin II (AII). When the contact time was increased, a greater degree of antagonism of AII was observed, suggesting that GR117289 is slow to reach equilibrium. A pKB of 9.8 +/- 0.1 was calculated for GR117289 after 3 h incubation. GR117289 (1 microM) did not affect contractile responses to phenylephrine or 5-hydroxytryptamine (5-HT) in the rabbit aorta. 3. GR117289 (1 nM) alone caused a marked suppression and a slight rightward displacement of the AII concentration-response curve. Co-incubation with the competitive, surmountable AT1 receptor antagonist, losartan (10 nM, 100 nM and 1 microM), resulted in a concentration-related upward and rightward displacement of the concentration-response curve to subsequently administered AII. In separate experiments in which preparations were pre-incu...Continue Reading


Apr 1, 1991·Hypertension·N E RhalebD Regoli
Jan 1, 1990·Journal of Cardiovascular Pharmacology·M de GasparoB Kamber
May 31, 1991·Biochemical and Biophysical Research Communications·A T ChiuP B Timmermans
Jan 1, 1989·Journal of Cardiovascular Pharmacology·K K GriendlingR W Alexander
May 1, 1985·Circulation Research·C J Homcy, R M Graham
Nov 15, 1988·European Journal of Pharmacology·A T ChiuP B Timmermans
Sep 1, 1980·Analytical Biochemistry·P J Munson, D Rodbard

❮ Previous
Next ❯


Feb 23, 1993·European Journal of Pharmacology·J Clapham, G J Kilpatrick
Jul 4, 1995·European Journal of Pharmacology·K L ClarkG M Drew
Oct 1, 1994·Trends in Pharmacological Sciences·M J RobertsonP Leff
Jul 18, 1995·European Journal of Pharmacology·A R RenzettiA Subissi
Sep 18, 2002·Biochemical Pharmacology·Ilse VerheijenGeorges Vauquelin
Jun 17, 2000·European Journal of Pharmacology·A U AsgharD S McQueen
Jan 14, 1997·European Journal of Pharmacology·M OjimaK Nishikawa
Jul 23, 1997·European Journal of Pharmacology·P M VanderheydenG Vauquelin
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Jan 1, 1997·Fundamental & Clinical Pharmacology·Y NozawaR Kimura
Jul 1, 1993·British Journal of Pharmacology·F H MarshallJ C Barnes
Jan 1, 1994·British Journal of Pharmacology·A HilditchM J Robertson
Mar 1, 2001·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Georges VauquelinPatrick Ml Vanderheyden
Apr 23, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·P M VanderheydenG Vauquelin
Apr 8, 2006·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Georges VauquelinIsabelle Van Liefde
Feb 24, 2001·Journal of Receptor and Signal Transduction Research·M J Robertson
Jan 14, 2004·The Journal of Pharmacology and Experimental Therapeutics·Mark C KowalaJohn E Macor
Dec 5, 1997·Journal of Cardiovascular Pharmacology·K TamuraK Hashimoto
Jun 1, 1996·The Annals of Pharmacotherapy·K L Schaefer, J A Porter
Dec 21, 2002·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masaaki KimuraYasuo Isomura
Feb 2, 1996·Journal of Medicinal Chemistry·R R WexlerP B Timmermans
Nov 5, 1997·Journal of Medicinal Chemistry·L MaletínskáE Escher

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.